Halozyme Therapeutics — Oct 31, 2024 release

For the full year 2024, the Company expects: • Total revenue of $970 million to $1,020 million, representing growth of 17% to 23% over 2023 total revenue primarily driven by increases in royalty revenue, collaboration revenue and growth in product sales from XYOSTED ® . Revenue from royalties of $550 million to $565 million, representing growth of 23% to 26% over 2023. • Adjusted EBITDA of $595 million to $625 million, representing growth of 40% to 47% over 2023. • Non-GAAP diluted earnings per share of $4.00 to $4.20, representing growth of 44% to 52% over 2023. The Company’s earnings per share guidance does not consider the impact of potential future share repurchases. Table 1. 2024 Financial Guidance   Previous Guidance Range New Guidance Range Total Revenue $935 to $1,015 million $970 to $1,020 million Royalty Revenue $520 to $555 million $550 to $565 million Adjusted EBITDA $555 to $615 million $595 to $625 million Non-GAAP Diluted EPS $3.65 to $4.05 $4.00 to $4.20 Webcast and Conference Call Halozyme will host its Quarterly Update Conference Call for the third quarter ended September 30, 2024 today, Thursday, October 31, 2024 at 1:30 p.m. PT/4:30 p.m. ET. The conference call may be accessed live with pre-registration via link: https://registrations.events/direct/Q4I7813747 . The call will also be webcast live through the “Investors” section of Halozyme’s corporate website and a recording will be made available following the close of the call. To access the webcast and additional documents related to the call, please visit Halozyme.com. About Halozyme Halozyme is a biopharmaceutical compan